Virometix AG is a privately held clinical-stage Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
In an increasingly global world there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges.
Our Products & Pipeline
In an ever more global world, where the risk of a disease being spread by travellers is high, vaccines have tremendous future growth potential in combating infectious as well as a range of chronic human diseases.
Virometix’ proprietary Synthetic Virus-Like Particle and Synthetic Antigen Mimetic technologies allows for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability.